Theraclion said yesterday its academic development partner, the University of Virginia, won an FDA nod to launch a study of the combined use of echotherapy high intensity focused ultrasound and immunotherapy drug pembrolizumab for treating patients with breast cancer. The study will examine the combined treatment’s effect on fighting breast cancer tumor cells, the French […]
Oncology
FDA approves diagnostic that simultaneously screens for multiple cancer biomarkers
The FDA said today that it awarded premarket approval to Thermo Fisher Scientific‘s (NYSE:TMO) next-gen sequencing-based test that can simultaneously screen tumor samples for biomarkers associated with 3 approved therapies for non-small cell lung cancer. The company’s Oncomine Dx Target Test evaluates 23 genes associated with non-small cell lung cancer. The tests results could help […]
Nanobiotix seeks to boost cancer care with nanoparticle-radiotherapy combo
Increasingly, pharma and biotech companies are looking towards personalized medicine to guide their portfolios, developing therapies designed to address the needs of individual patient populations. Nanobiotix (EMA:NANO) has chosen to look in the other direction, according to co-founder & CEO Laurent Levy. “What we have done in our company is trying to go for the opposite: […]
Cleveland Clinic spinout Infuseon inks deal with OncoSynergy
Infuseon Therapeutics inked a deal this week with OncoSynergy to evaluate a glioblastoma therapeutic with the Cleveland Clinic spinout’s novel delivery device. The alliance hopes to demonstrate proof-of-concept that OncoSynergy’s candidate can be successfully delivered directly to a patient’s brain using the device in a Phase I glioblastoma trial. Infuseon’s Cleveland Multiport Catheter, which won […]
Rubius snags $120m for red blood cell therapeutics
Rubius Therapeutics, a biotech engineering red blood cells as drug carriers, said today that it raised $120 million in an oversubscribed private financing round. The Cambridge, Mass.-based company plans to use its newly-acquired funds to support its Red-Cell Therapeutics portfolio and prepare for human clinical trials in 2018. “With this financing, Rubius is well positioned […]
BioDelivery Sciences brings novel drug delivery tech to pain management, opioid addiction
As the American public grapples with an ongoing opioid crisis, pain management companies are looking for ways to innovate their products in an attempt to avoid potential abuse. For years, BioDelivery Sciences International (NSDQ:BDSI) has developed mucoadhesive buccal films loaded with painkillers for pain management and addiction therapy. Now it is developing a buprenorphine depot […]
Blaze Bioscience touts Phase 1 data from pediatric oncology Tumor Paint BLZ-100 study
Oncology-focused biotech company Blaze Bioscience today released clinical data from the Phase 1 study of its Tumor Paint BLZ-100 in pediatric brain cancer patients, touting that the agent was well tolerated. Data from the study was presented at the 4th Biennial Pediatric Neuro-Oncology Basic and Translational Research Conference in New York. The BLZ-100 is the […]
Pulmatrix inks licensing deal for novel inhaled kinase inhibitors
Pulmatrix (NSDQ:PULM) said today that it inked an exclusive, worldwide license agreement with Janssen Biotech subsidiary RespiVert. According to the deal, Pulmatrix will have access to the company’s portfolio of novel kinase inhibitors. The agreement covers respiratory and oncology indications for the drug candidates and Pulmatrix said it plans to take over the portfolio’s global […]
Nanoparticles use 2 mechanisms to boost immunotherapy
Cancer immunotherapy, a treatment approach that has gained momentum over the past few years, only helps a small fraction of patients. But researchers from the Johns Hopkins University School of Medicine have developed a nanoparticle that may one day help expand the patient population that benefits from immunotherapy. Immunotherapy usually falls into 1 of 2 […]
BTG touts digital patient engagement platform with TheraSphere treatment
BTG (LON:BTG) touted data last week from a pilot study of its digital patient engagement platform IO Loop in patients with primary hepatocellular carcinoma undergoing treatment with the company’s TheraSphere transarterial radioembolization therapy. The study found that patients experienced sustained quality of life up to 3 months after treatment. The company touted the study of […]